PepGen Inc. (PEPG)

Market Cap	48.38M
Revenue (ttm)	n/a
Net Income (ttm)	-89.98M
Shares Out	32.69M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	169,588
Open	1.610
Previous Close	1.610
Day's Range	1.450 - 1.610
52-Week Range	1.160 - 19.300
Beta	0.98
Analysts	Buy
Price Target	10.33 (+597.97%)
Earnings Date	May 13, 2025

About PEPG

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2022
• Employees: 81
• Stock Exchange: NASDAQ
• Ticker Symbol: PEPG
• Website: https://pepgen.com

Analyst Forecast

According to 3 analysts, the average rating for PEPG stock is "Buy." The 12-month stock price forecast is $10.33, which is an increase of 597.97% from the latest price.

Price Target

$10.33

(597.97% upside)

Analyst Consensus: Buy